Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid 1 Trial
NCT04786600Phase 2Terminated
- Sponsor
- University of Florida
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic colorectal cancer (mCRC) (2 arms), sponsored by University of Florida. Primary endpoint: Overall Survival at 580 days. Started Mar 2022; status: terminated.
02
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04786600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04786600.